Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-27T12:39:34.214Z Has data issue: false hasContentIssue false
  • English
  • Français

X-ray powder diffraction data for a DACH Pt nitrate, cis-[bis(acetonitrile)]-[(1R,2R)-1,2-diaminocyclohexane-κN, κN′]platinum(II)nitrate (1:2) monohydrate

Published online by Cambridge University Press:  05 March 2012

R. Pažout ,
J. Maixner ,
P. Kačer  and
J. Housková
R. Pažout*
Affiliation:
Central Laboratories, Institute of Chemical Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic
J. Maixner
Affiliation:
Central Laboratories, Institute of Chemical Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic
P. Kačer
Affiliation:
Department of Organic Technology, Institute of Chemical Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic
J. Housková
Affiliation:
Department of Organic Technology, Institute of Chemical Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic
*
a)Author to whom correspondence should be addressed. Electronic mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

X-ray powder diffraction data, unit cell parameters, and space group for a new platinum-based anticancer complex cis-[bis(acetonitrile)]-[(1R,2R)-1,2-diaminocyclohexane-κN, κN′]platinum (II)nitrate (1:2) monohydrate, cis-[Pt(C2H3N)2(C6H14N2)](NO3)2·H2O, are presented [a=12.638(3) Å, b=12.153(2) Å, c=11.881(3) Å, β=95.145(4)°, space group P21, cell volume=1817.5 Å3, and Z=4]. All measured lines were indexed and are consistent with the P21 space group. No detectable impurities were observed.

Keywords

X-ray powder diffractioncrystal structureDACH Pt acetonitrile nitrate hydrate
Type
New Diffraction Data
Information
Powder Diffraction , Volume 26 , Issue 1 , March 2011 , pp. 66 - 69
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abu-Surrah, A. S. and Kettunen, M. (2006). “Platinum group antitumor chemistry: Design and development of new anticancer drugs complementary to cisplatin,” Curr. Med. Chem.CMCHE7 13, 1337–1357.10.2174/092986706776872970CrossRefGoogle ScholarPubMed
Boultif, A. and Louër, D. (2004). “Powder pattern indexing with the dichotomy method,” J. Appl. Crystallogr.JACGAR 37, 724–731.10.1107/S0021889804014876CrossRefGoogle Scholar
Galanski, M., Arion, V. B., Jakupec, M. A., and Keppler, B. K. (2003). “Recent developments in the field of tumor-inhibiting metal complexes,” Curr. Pharm. Des.CPDEFP 9, 2078–2089.10.2174/1381612033454180Google ScholarPubMed
Ho, Y. P., Au-Yeung, S. C. F., and To, K. K. W. (2003). “Platinum-based anticancer agents: Innovative design strategies and biological perspectives,” Med. Res. Rev.ZZZZZZ 23, 633–655.10.1002/med.10038CrossRefGoogle ScholarPubMed
Pažout, R. and Maixner, J. (2010). “X-ray powder diffraction data for a DACH Pt iodide, cis-[diiodo(1R,2R)-1,2-diaminocyclohexane-κ N, κ N′] platinum(II),” Powder Diffr.PODIE2 25, 368–370.10.1154/1.3504593CrossRefGoogle Scholar
Smith, G. S. and Snyder, R. L. (1979). “F N: A criterion for rating powder diffraction patterns and evaluating the reliability of powder indexing,” J. Appl. Crystallogr.JACGAR 12, 60–65.10.1107/S002188987901178XCrossRefGoogle Scholar